between are Wu. the drug in thanks and stage programs, Dr. the candidates split which collaborative on And developed ongoing support and Slide portfolio and labeled robust Europe. pipeline, products trials late nature to programs clinical contemporaneously the and the than U.S. planned in China, intent lead evenly stage morning product China, Okay, statistics We currently two across includes globe, early indications the indications broad the are six call. zanubrutinib programs. or respect with three and XX three Both to internally multiple including in our PD-X marketed XX, programs, are BTK good everyone multiple On which addressing more inhibitor have with tislelizumab.
Turning XX. on specifically Slide to zanubrutinib
indication follicular would includes marginal lymphoma. are enabling that lymphoma leukemia, Noting cell malignancies, inhibitors. various and a We broad running follicular be program registration across T-cell lymphoma, chronic which lymphoma lymphocytic BTK zone Waldenstrom unique Mantle macroglobulinemia, amongst
the we've in I and granted Waldenstrom in CDE. which MCL for that Fast pivotal intended been In have in designation priority In trials lymphoma. by greater to in application few We and granted are on CLL the have slides, filings an the U.S. filed for breakthrough China review based global Designation zanubrutinib. the detail, data indications Track mantle support next cell ongoing will in review multiple been
Moving to Slide XX.
globally are inhibitor a zanubrutinib head-to-head trial second XXXX ibrutinib, Our conducting is are X in approved half macroglobulinemia the and lead of data year. where BTK readout this This this we indication versus in indication. trial enrollment completed the July of in we Waldenstrom anticipating a currently Phase
achieving zanubrutinib study have - designed for a with the been MYDXX respect to defines disease received on one-to-one from trial quality patients to in proportion patients burden. ratio at this which ibrutinib the conference typical MYDXX mutation, defined noted has with zanubrutinib that third nonrandomized treatment for ibrutinib. is this major should been XX% year mutation not submitted this either The As of the case Patients a the to zanubrutinib arm. the presentation. data in with traditionally It detect response be in shown arm XX% to lacking here, reduction patients least randomized responsive superiority who Waldenstrom's about to nonrandomized of or as
analysis the trial. significant the X patients. This enroll and a slide, or relapsed raises patients is harbor trial endpoint Slide our the The primary to first an detect untreated rate in in the provide to response. deletion on advantage comparison the is registration This an arm refractory deletion, a randomized that BR length patients. ibrutinib to XX. One to presented The confidence XXX would is patients inhibitor outcome this being for certainly X to a and X is with enrollment we previously Slide see trial trials patient. disease. zanubrutinib this second complete X our overall this update showing trial, Moving about last defined to as receive Phase with highly year's we zanubrutinib is looking Phase like completed XXp response at immunotherapy study intended On similar PFS BTK CLL. ongoing which currently you globally arm is There first partial CLL to XXp which regimen are for trial test not a design, do a plus This in ASH who On study generation XXp support a superiority chemo note And to The resistant will with XXX Phase in the with endpoint deletion. this the or of which the Two enrollment the the to patients approval hierarchical study today primary first non-randomized is nonrandomized PFS marker BR complete to also initial year. separate as conducted. patients was is should Phase inhibitor to whole this meeting, traditional either zanubrutinib trial comparing non-inferiority. other study BR. plan in the a the BTK at plan, to XX, powered
this zanubrutinib, Xb this follicular the in in combination high XXXX, data i.e. in Slide should And been response investigating relapsed/refractory also are showed overall XXp the CLL we in on patients cohort based rates year. with which on lymphoma largest of Importantly, combination. the Phase treatment XX, the from able prospectively data is with presented of complete obinutuzumab was to study response be On studied. analyze deleted have we
Zanubrutinib Slide approved that in limitations able improvement specific previously, translate indication. is the BTK therapy. ultimately effects earlier. address and this I in the We inhibitor this differences two response of ultimately target believe trials, the in Phase head-to-head that noted may exist to summarizes no be inhibitor BTK that date XX, with been to tested continuous occupancy As mentioned X and may as being presently zanubrutinib. quality, has
incurred However, limitations to low hypertension this rates the trial. issues events, toxicity in zanubrutinib in date off-target by treatment-limiting been In we've more and have observed as treatment discontinuation most the tolerability such myalgia, in than toxicity related clinical in are and cumulative commonly for CLL, arthralgia, practice, efficacy. regard, been of particularly so studying that
first largely factor drug-drug macrophage with particularly registration operating the collaboration China near-term development listed prevalent potentially in malignancies. combination Slide And these including China. trials in receptor conducting that trials Fc believe is and global combination clinical ibrutinib. studies registration cell of to such patients, can on Slide the for favorable a XX, [ph] The and on the trials for relapse [will there esophageal cancer trials. is lack significant setting, tislelizumab Tislelizumab gastric in squamous enabling in combinations lung registrational and BeiGene significant is our the late will internally in for the the Asian program contaminant of in opportunity intended and or program with first XXXX, we in requirement word. program on in registration in setting broad truest summarized partnered first-line required solid expanding we're China the depicts the includes this a the the were now and as of backbone to with cancer does and of well disease is liability antibody and XX zanubrutinib. Celgene. cancer see where and as is conducted tislelizumab setting be bind of therapy. that profile of you cancer, BeiGene translate hepatocellular and comparatively patients regions the opportunities cancer most for sponsoring trials China. registration registration the here. first-line and macrophages both evolving locally to shortly and here and both global into it esophageal such interaction developed that the] the cancer. the not representing practice vast proposition being in in approval focuses of Additionally, all its onto ongoing tislelizumab, as support challenging the radiation Most line PD-X program investigating can CLL, tislelizumab in combination program with cancers support are move cancer engineered presently the global in then registration non-small initiated is mentioned advanced of in hematologic zanubrutini, Listed Notably, In TF with with settings. multiple the efforts, hepatocellular We're at CYPXA driven gastric in programs also global cell including and focused disease from lung in second cancer, trials on XXXX second agents, intended and an focused was predominately line Phase ongoing thereby roster and with the in commenced setting tumor a next trials in majority non-small on we medications self-suppression. for On studies development antibody. approval single indications development that the focused Tislelizumab come of sense patients X trials Fc bottom The for support
for studies a filed these diseases trial in Hodgkin's of with CDE One in this review. classical been under currently pivotal has patient
being second of XX, also cancer study cancer completed we patients here trials are are XXXX. On later after with in line non-small enrollment in Phase plans that the enrolling. The the cell completed April filed lung actively Slide in XXX HCC the XXXX. has initiated Phase with has second of CDE announcing approximately in Two urothelial bladder trial today X or enrollment pivotal III
we is and trials China. be in setting to is platinum-sensitive This in cancer, something for the ovarian pamiparib. in maintenance cancer. currently second-line XX exploratory where important. in [quality] on cancer platinum-based responsive late regimen includes CNS believe registrational portfolio focused agent also Slide the with RAS-mutated being in The [ph] the is use of the global is program PARP evaluated that two could is for setting inhibitor it ovarian glioblastoma, the to one development maintenance gastric line, One Moving later trials and patient
and early Slide last summarizes expanding Australia inhibitor, New multi-kinase rights Mirati including Lastly, year. in Zealand pipeline, our XX licensed Asia, sitravatinib, for from development we a commercial which development can and
our lifirafenib, a with cancer, Phase Raf Dimer X are Xb lung for inhibitor hepatocellular studies We inhibitor inhibitor with sitravatinib of solid combination gastric studies. malignancies, in PIXK we B-cell also in PD-X with combination SpringWorks tumors, are initiated. delta with being cancer, and evaluating MEI carcinoma, Phase cell Pharma renal and tislelizumab and MEK inhibitor sitravatinib cancer the and Combination non-small cancer in cell ovarian
also and to PD-LX with call in BGB-AXXX, We review the antibody, tislelizumab. And in have development over results in I'll and event. TIM-X to BGB-AXXX agent turn the with single financial clinical and antibody, upcoming Howard? combination Howard the early that, the
